The findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.
The vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut. This data can be sent to a mobile phone.
Capsule co-inventor, RMIT’s Dr Kyle Berean, said the second human trials have revealed information about gas production in the gut previously masked when measured indirectly through the breath.
“The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,” Berean, who is also Chief Technology Officer at Atmo Bioscience, said.
“Being able to measure these biomarkers at concentrations over 3,000 times greater than breath tests is quite astonishing.
“Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.”
Intestinal gases are currently used to diagnose disorders including small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption.
Of the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime, almost a third remain undiagnosed due to a lack of reliable tests available to gastroenterologists.
Study lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.
“This gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms,” Kalantar-zadeh said.
Findings from the first human trials revealed the stomach releases oxidising chemicals to break down and beat foreign compounds that are staying in the stomach for longer than usual. Such an immune mechanism has never been reported before.
This second paper made a direct comparison between measuring hydrogen production within the gut via the gas-sensing capsule and indirect measurement through breath testing.
Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.
Melbourne based start-up Atmo Biosciences is set to commercialise this revolutionary technology.
The trials were conducted with colleagues from Monash University. The findings have been published in the medical journal Alimentary Pharmacology and Therapeutics (DOI: 10.1111/apt.14923).
Story: Grace Taylor
